Tag Archives: integrator

Markets Will Always Present Opportunities For The Patient Investor

There is a theory that markets perfectly process external information such that they always serve up fair valuations for a stock. I beg to differ. I have had serious reservations about the validity of the efficient market hypothesis for a long time. I believe that markets overreact to negative news that is not stock specific. I’ll provide a couple of examples where I think this is the case. Alibaba I have had my eye on Alibaba’s (NYSE: BABA ) stock for a considerable period of time. Ever since the IPO in fact, I had been looking for opportunities to own the stock. However, time and again, the company just proved itself too be too far out of my strike zone, and traded above a valuation at which I would be interested to make a purchase. I didn’t let that disturb me too greatly as I felt the next scare about China related growth or fears of a worldwide recession would bring the company back to a price that I was more comfortable buying. It’s not hard to see why I was so keen on the Alibaba business. The company benefits from strong network effects, courtesy of being the dominant e-commerce play in China. At latest count, BABA had roughly 367M buyers across its marketplaces. Taobao in particular enjoys strong brand loyalty among a younger generation of Chinese consumers. A platform with the greatest number of buyers attracts the greatest number of sellers and provides strong monetization for Alibaba. Having such a dominant platform makes it hard for competitive platforms to find a place. Others either need a clear value proposition to supersede BABA, such as better pricing, or offer services in a small niche that Alibaba doesn’t cater to. What’s interesting to note is that the Alibaba business has been on a constant upswing in recent times. Revenues have grown at a strong pace over the last five years, averaging just under 30% annually. Operating income and EPS have shown similar levels of growth over the last five years. Most recent quarterly growth has been outstanding as well, with revenue and operating income increasing 30% year on year. BABA’s growth potential remains immense. China’s e-commerce sales still only represent about 10% of total retail sales, implying that there is still a long way for digital commerce to go. Yet looking at the movements in the Alibaba stock price suggests a market that is confused by the prospects for this business. Alibaba’s stock was down 20% in 2015. In the year to date, the stock is down another 7%. However, it was a lot worse just several weeks ago when the stock was down almost 26% year to date. Alibaba’s prospects haven’t changed at all in the intervening few months. There have been no new competitive threats, no profit warnings and no stock specific bad news. Yet the stock plunged almost 25% in the year thus far on concerns over poor Chinese data, even though the underlying business is in glowing health. Even if poor economic data from China did indicate a slowing down of the economy, does that justify marking down a high quality business growing at 30% annually by almost 25%? Baidu Another victim of market irrationality was Baidu (NASDAQ: BIDU ). Baidu is the “Google of China” and controls close to 80% of the overall share of internet search in the country. This provides a natural monopoly for the business. Users are likely to continue to leverage the dominant search engine if it continues to provide them with the most relevant search results. Having the most users in turn tends to attract the largest share of advertisers willing to pay the most to advertise. The company has a great track record of long-term growth. Average annual revenue growth over the last 10 years has come in at close to 82%. Revenue growth over the last couple of years has still averaged over 40%. Yet, the stock has been hammered. It was down 17% in 2015, and down almost another 26% at various points during 2016. While the stock has significantly bounced back in the last few weeks, Baidu was another name that sold off in the absence of specific information impacting the underlying business. With the Chinese online advertising market set for steady growth over the coming decade, market hand wringing over Baidu’s prospects arguably set up an attractive share valuation for patient, long-term oriented investors. I have given examples of 2 companies that I think have compelling growth stories that should be well placed for the long term, which the market chose to mark down on no real company specific news. I’ll offer one further example of a company that I believe has been overly marked down on a company specific event. Chipotle Chipotle (NYSE: CMG ) is a relatively rare success story in the retail space, as it is one of the few businesses that has managed consistent revenue growth at close to 20% annually over the last decade. This also isn’t a case of a business with growth that has started strong and been progressively declining. The business has seen 3-year average revenue growth top 20% for each of the last few years. Chipotle’s gross margins and operating margins have been responsible for juicing earnings growth. It’s amazing that gross margins have increased from 18.5% to almost 27% in the last decade. Even more impressive is that operating margins have grown from 4% to 18.5% in that same time. However, a spate of E. coli and noro virus scares have decimated the company and the company’s stock. Chipotle’s stock plunged from close to $750 in 2015 to a low point of $400 which was reached early in 2016. That’s a fall which is just shy of 50%. This is another example of a business that I have really liked, which was trading at a valuation that I wasn’t comfortable with. However, that large share price drop was tough to ignore. Now these sorts of E. coli scares and virus epidemics are actually relatively common place in the fast food industry. A lack of hygiene amongst employees and problems in the supply chain make these incidents unavoidable. In fact, Jack In The Box (NASDAQ: JACK ) had a particularly nasty virus outbreak a number of years ago that caused the deaths of close to 10 people. Comparatively speaking, Chipotle’s problems are thankfully relatively less severe, but nonetheless, its stores are currently sparsely populated and the company’s earnings have suffered. Thankfully, consumers have relatively short memories, and they typically return back to these stores after a period of time. Lost consumer traffic takes about a year to recover, but consumers eventually return. The market seems to be pricing Chipotle on the basis that it will see severe and sustained consumer losses that will hurt long-term growth. I think a 50% reduction in business value is an overly pessimistic assessment of the business’s prospects and overstates how long a consumer’s memory is. Markets always offer up opportunities for the patient investor. The key is to be willing to wait for them.

Project $1M: Achieving A $1M Portfolio With Growth Stocks Pt. 3

Summary I’ve created Project $1M to try and attain a $1M capital base from growth stocks in 11 years. I’m focused on including stocks that have a moat and some strong growth drivers. I will introduce the final set of stocks in this update. I previously introduced the concept of my growth oriented model portfolio in a previous article. The focus of that portfolio was directed toward achieving a $1M capital base in approximately 11 years, starting from a base of $217,500. I previously introduced the first 6 stocks in the portfolio here , and the next 6 stocks in the portfolio here . I’d like to introduce the final set of stocks in the Project $1M portfolio here and show how the portfolio stands. My Criterion In addition to companies with moats and strong barriers to entry, I set a specific focus on companies with high returns on invested capital and that were generally achieving double-digit growth with respect to net income and earnings per share. My thinking here was that these types of companies would be likely be able to continue earning above double digit earnings while maintaining their market multiples, and thus generate strong rates of capital growth. The Remaining Companies Westinghouse Air & Brake (NYSE: WAB ) is a technology supplier to the freight rail and the passenger transit industries. The company provides engine cooling, braking and other design and engineering services. Wabtec holds a dominant market share position in North America for the supply of technology to the rail industry. In some specific component segments, such as pneumatic braking systems, Wabtec is part of a strong duopoly along with Knorr Bremse. This dominance is reflected in the significant positive trend in gross margin and operating margin for Wabtec over the last decade. Positive Train Control represents the next revenue driver for the company. Positive Train Control refers to the requirement that certain operational functions of a train be capable of being monitored and controlled electronically. Wabtec has almost tripled revenues from $1.03B in 2005 to over $3.04B in 2014, representing an annualized growth of close to 14%. The company derives returns on equity and returns on invested capital that are consistently over 15%. Celgene (NASDAQ: CELG ) is a strong player in the biotechnology space, with a portfolio of drugs targeted toward cancer and inflammatory conditions. The company’s Revlimid franchise is a blockbuster and delivered over $5B in revenue in 2014. Revlimid has received approvals for the treatment of a variety of conditions including lymphoma and myeloma. With patent protection on the franchise likely to last well beyond the end of the decade, Celgene is poised for long term growth. Celgene’s return on equity have been hovering around 30% for the last few years, which indicates that it is a good steward of shareholder capital. Celgene has managed strong double digit revenue growth for the last decade. I don’t see too many reasons why this won’t be the case for the coming decade as well. Medidata (NASDAQ: MDSO ) solutions provides cloud based simulations and prototyping for life sciences. Medidata provides a valuable service for company’s engaged in drug discovery by helping them to simulate and prototype the effect of a given molecular combination quickly and more cost effectively than with traditional methods. The company has been growing revenues at almost 20% annually, with gross margins seeing a positive upward trend, and hovering at around 75%. With the continued push for faster drug development and continued pressure on traditional pharmaceutical companies, the need for Medidata’s product offerings will only continue to grow. Vipshop (NYSE: VIPS ) is discount e-commerce retailer in China that has pioneered the concept of flash sales. The company aggressively marks down oversupplied or out of season stock, which it makes available on its platform. Vipshop has a particular focus on pushing product to consumers in Tier 3 or Tier 4 cities in China, where there are typically no malls selling brand name product. The company’s rate of growth has been nothing short of extraordinary, with revenue growth in excess of 100% annually for the last few years. While that will undoubtedly moderate overtime, Vipshop occupies a unique niche in the Chinese e-commerce market, With returns on equity in excess of 40%, and a long runway of growth ahead, I think Vipshop could be poised for good long term returns. Zhaopin(NYSE: ZPIN ) provides an online recruitment platform in China. Zhaopin offers online recruitment services, including executive search and campus recruitment. Zhaopin has maintained a strategy of moving into lower tier cities in the quest to drive further revenues. While LinkedIn’s (NYSE: LNKD ) entry into China remains a long term threat for this company, Zhaopin’s early entry and focus on smaller tier cities should provide a competitive edge that allows the company to continue to grow profitably for a number of years. The company has returns on invested capital of over 25%, with revenue growth also in excess of 20%. Polaris (NYSE: PII ) designs and manufactures off road vehicles and other sport utility vehicles including snow mobiles, ATVs and motorcycles. Polaris has a well deserved reputation for design excellence and innovation, which has helped the company stand out in an increasingly crowded market. Polaris has demonstrated a track record of financial discipline over the last decade. Gross margins have shown sustained increase, rising 600 bp over the last decade. This is coupled with returns on invested capital that have exceeded 40% over the last few years. When combined with strong double digit revenue growth over the last decade, Polaris looks quite attractive for future returns. United Therapeutics (NASDAQ: UTHR ) produces drug therapies for patients with chronic conditions and is focused on the unmet needs space. The company currently produces drugs for pulmonary hypertension, congenital heart problems and neuroblastoma. While the company remains exposed to the risk of generics eventually making their way into some of the key niches that the company currently occupies, UHTR is looking to expand the markets it currently serves, and is even looking at the manufacture of artificial organs as a new line of business. The company has grown revenues in the high double digits for the last decade, with returns on invested capital over 40%. This write up concludes the initial set of positions for Project $1M, which is currently fully invested. Below is what the portfolio currently looks like. I will provide periodic updates on portfolio performance and any new positions that are initiated, or existing positions that are existed. Name Shares Held $ Cost Per Share $ Total Cost $ Market Value $ Unrealized Gain/Loss Since Purch % Unrealized Gain/Loss Since Purch Baidu Inc ADR 54 187.47 10,123.38 11,161.26 1,037.88 10.25 Celgene Corp 122 122.71 14,970.62 13,848.22 -1,122.40 -7.5 Core Laboratories NV 64 116.33 7,445.12 7,190.40 -254.72 -3.42 Facebook Inc Class A 99 101.97 10,095.03 10,624.68 529.65 5.25 LinkedIn Corp Class A 42 240.87 10,116.54 10,620.54 504 4.98 MasterCard Inc Class A 305 98.99 30,191.95 30,347.50 155.55 0.52 Medidata Solutions Inc 174 43 7,482.00 7,830.00 348 4.65 Mercadolibre Inc 102 98.37 10,033.74 12,377.70 2,343.96 23.36 Moody’s Corporation 156 96.16 15,000.96 16,277.04 1,276.08 8.51 Novo Nordisk A/S ADR 235 53.18 12,497.30 12,861.55 364.25 2.91 Polaris Industries Inc 89 112.34 9,998.26 9,386.83 -611.43 -6.12 Priceline Group Inc 7 1,454.00 10,178.00 8,970.71 -1,207.29 -11.86 ResMed Inc 174 57.61 10,024.14 10,286.88 262.74 2.62 Starbucks Corp 201 62.57 12,576.57 12,459.99 -116.58 -0.93 United Therapeutics Corp 51 146.63 7,478.13 7,709.67 231.54 3.1 Vipshop Holdings Ltd ADR A 243 20.52 4,986.36 3,973.05 -1,013.31 -20.32 Visa Inc Class A 256 77.58 19,860.48 20,528.64 668.16 3.36 Westinghouse Air Brake Technologies Corp 121 82.87 10,027.27 9,285.54 -741.73 -7.4 Zhaopin Ltd ADR 314 15.19 4,769.66 4,788.50 18.84 0.39 Project $1M 217,855.51 220,528.70 2,673.19 1.23